Venture forces invest millions in new type of treatment for particularly aggressive form of cancer
PRESS RELEASE, COPENHAGEN 18TH OCTOBER 2023
A syndicate consisting of the Lundbeck Foundation BioCapital, EIR Ventures, EIFO and UCPH Ventures has just made an investment in the Danish biotech company Dania Therapeutics (Dania Tx). The company is based on research from renowned professor Kristian Helin and dr. Karl Agger originating from Helin’s former research group at the University of Copenhagen. The ambition is to develop a treatment for acute myeloid leukaemia, which also holds potential for treatment of other types of cancer.
Latest News
Upcoming Events
2nd December 2026
London, UK
BMCS/SMR Recent Trends in Medicinal Chemistry and Enabling Technologies
Attendee:
Ben Davis PhD
Research Fellow and Director of Business Development
Ben Davis PhD
Research Fellow and Director of Business Development
Dr Ben Davis is an NMR spectroscopist and biophysicist by training, although since 2022 he has focussed on Business Development. However, he still maintains an active interest in developing new methods to enable Fragment Based Drug Discovery, particularly against challenging targets. Ben studied for his PhD in protein folding with Professor Alan Fersht at Cambridge University, and then studied molecular interactions at UCL before joining RiboTargets, now Vernalis, in 1998. He has contributed to seven books on FBDD since 2012, and has been an author on more than thirty scientific publications. He is a frequent speaker at scientific conferences.